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STANDARD COSTS AND RESOURCES ALLOCATION IN ATTAINMENT OF
TARGET LIPID LEVELS AMONG EXPERIENCED STATIN USERS: RESULTS FROM
THE STAR STUDY (STATINS TARGET ASSESSMENT IN REAL PRACTICE)
Degli Esposti L, Buda S, Sangiorgi D, Degli Esposti E
CliCon Srl, Ravenna, Italy
OBJECTIVES: The absolute Cardiovascular Disease (CVD) risk is a leading cause of
death. Guidelines recommend treatment with lipid-modifying drugs for patients
with an elevated CVD risk, since cholesterol target attainment allows a reduction of
events. Our aim was to analyze the economic impact (drugs and hospitalizations)
of LDL target attainment. METHODS: A multicenter, retrospective observational
study using administrative and laboratory databases (1.1 million health-assisted
individuals) was conducted. The enrolment date for a given patient was the last
date in year 2009 in which the patient reached its LDL therapeutic target, accord-
ingly to its CVD profile. Patients without statins prescriptions within the 18 months
preceding the enrolment date were excluded. RESULTS: A total of 17,243 patients
were enrolled (54.6% males, age 69,310,0). The annual standard cost for statins
and cardiovascular hospitalizations to achieve the therapeutic target, obtained
from a multivariable regression model, was €698. The standard annual require-
ments for welfare benefits, calculated on the basis of this approach, had a value of
14% lower (€2,914,807) than the current value of expenditure. This resource saving
was attributable to a reduced spending in hospital admissions, likely due to a correct
prevention. The standard requirements, however, showed a different items composi-
tion of expenditure; particularly, we observed an increase of the pharmaceutical ex-
penditure by 13% (€1,022,825) compared to the current value. 42% of patients did not
reach target (13% adherents, 29% non-adherents), 33% reached target (although non-
adherents), consuming 28% of the total expenditure, suggesting an over-consumption
of resources (27% used high dosages statins); this expenditure could be reallocated
within the non-target groups, increasing the adherence and switching to other statins
and/or dosages. CONCLUSIONS: The applicability of this approach and the cost-
saving achievement, needs the adoption of a reimbursement system that rewards
the care pathway not only in its individual parts (ie, drug treatments).
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ANALYSIS OF HOSPITAL-SPECIFIC DRG PAYMENTS FOR STROKE ACCORDING
TO UNITED STATES MEDICARE PERSPECTIVE
Blein C, Marty R, Roze S
HEVA, Lyon, France
OBJECTIVES: To calculate US-hospital specific DRGs payments for in-patient stays
with a primary diagnosis of stroke and assess its variability according to Medicare
inpatient prospective payment system (IPPS). METHODS: The ICD 9-CM diagnosis
codes related to stroke were selected. The coding rules and algorithms of the Medi-
care severity DRG Grouper (version V29) were analyzed to identify the distinct
stroke related Diagnosis Related Groups (DRG) depending on co-morbidities and
concomitant diagnosis. According to IPPS rules, inpatient hospital services are paid
at a predetermined rate. This latter is calculated by multiplying a DRG-relative
weight with operating and capital base payments rates. These rates are adjusted on
several hospital features such as geographical area, share of low-income patients
served, and involvement in medical education. These hospital specific DRG base
payments were implemented for each Medicare provider listed in the Federal reg-
ister, based on their information found in the 2012 PPS Impact files. Weighted
average tariffs across DRG, based on discharges rates reported in the Health care
Cost and Utilization Project (HCUP) statistics were generated and the variability of
DRG payments was also assessed through descriptive statistics. RESULTS: Distinct
DRGs are assigned during inpatient stay for stroke and their average payments to
Medicare providers ranging from $4,288 to $18,296. Overall weighted mean (median)
payments for stroke were $7,193 ($6,728) across all DRGs and Medicare providers.
DRG-tariffs distributions by region as well as other hospital characteristics (size, urban
versus rural location, teaching status) highlighted the disparities related to each of
these factors and their relative impact. These findings were compared with HCUP
aggregated statistics related to costs and hospital charges. CONCLUSIONS: Calculat-
ing hospital specific DRGs according to the US-Medicare prospective payment sys-
tem enable to get reliable cost inputs for health-economic models and relevant for
adaptation to US-local settings (regional or even hospital based).
CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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COMPLIANCE WITH WARFARIN THERAPY BY AUSTRALIAN PATIENTS WITH
ATRIAL FIBRILLATION
Ortiz MS1, Calcino G2, Germanos P3
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OBJECTIVES: To study warfarin compliance by Australian patients with Atrial Fi-
brillation (AF). METHODS: Longitudinal assessment of Pharmaceutical Benefit
Scheme (PBS) claim records provided by Medicare Australia. We analysed a 10%
random sample of all Australian long-term health concession card holders who
had taken an anti-arrhythmic medication for AF prior to a new initiation of warfa-
rin (time window October 2006 to September 2007), and for whom warfarin had not
been dispensed in the 12 months prior to the initiation. Regimen complexity was
assessed using the number of strengths of warfarin taken in a 90-day period. Treat-
ment compliance was assessed using: the proportion failing to fill a second pre-
scription; median persistence time with medication: long term persistence at 30
months. Treatment cessation was defined as 6 months without a warfarin
prescription. RESULTS: The PBS Claims database yielded information on 1,108 con-
cessional AF patients newly initiated on warfarin. These AF patients were initiated
on 2.4 different strengths of warfarin in the first 3 months and the regimen com-
plexity was 2.0 strengths 12 months later. Australian PBS claims data showed that
13% stopped warfarin after the first script. Median persistence to warfarin was 22
months, while long term persistence (30 months) was around 42%. Decreasing the
cessation criteria from 6 to 3 months revealed large treatment gaps in 16% of
warfarin patients at 2 years. CONCLUSIONS: There is a significant problem with
complex dosing regimens and poor persistence in AF patients taking warfarin.
Warfarin regimens tend to be complex with AF patients averaging 2 or more
strengths of warfarin. Not only do the majority of AF patients stop warfarin within
2 years, a further one in six had large treatment gaps. If AF patients fail to take their
anticoagulation therapy regularly, then this will substantially increase the risk of
adverse outcomes including stroke.
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A RETROSPECTIVE STUDY OF COMPARING COMPLIANCE AND PERSISTENCE OF
FREE COMBINATION ANTIHYPERTENSIVE THERAPY VERSUS SINGLE-PILL
COMBINATION: KOREAN CASE
Min J1, Min K2, Hong J3, Kim EG3, Shin K4, Yang BM3
1Institute of Health and Environment, Seoul National University, Seoul, South Korea, 2Ajou
University School of Medicine, Suwon, South Korea, 3Seoul National University, Seoul, South
Korea, 4Novartis Korea, Seoul, Seoul, South Korea
OBJECTIVES: Antihypertensive single-pill combination (SPC) therapy is known to
be associated with better compliance and persistence compared to free-drug com-
binations (FC). However, due to differences in blood pressure, occurrence of hyper-
tension-related diseases, diet, and lifestyle, applying the existing results from a
Western population to a Korean population may not be acceptable. In this study,
we compared the compliance and persistence of SPC versus FC using the 2009 data
of the Health Insurance Review Agency National Patient Sample. METHODS:
Among a total of 65,477,122 prescription claims, patients who were prescribed at
least one SPC or FC in 2009, were more than 40 years old and had no history of
hospitalization, surgery, or cancer numbered 9,822 and 7,494, respectively. Com-
pliance was measured using the proportion of days covered (PDC) and calculated as
the proportion of days a patient took the index drug within the 12-month follow-up
period in 2009. Persistence with therapy was measured as the number of days from
the index date to the therapy discontinuation date, which was defined as a gap in
therapy of 30 or more days. RESULTS: The overall average PDC was 0.58 for SPC and
0.59 for FC, which was not significantly different. However, compliance varied by
comorbidity status: patients who prescribed SPC showed greater PDC than those
who were prescribed FC. Notably, among patients with dyslipidemia, diabetes, and
chronic heart disease, compliance was significantly higher for SPC than for FC: 0.64
vs. 0.61 for dyslipidemia (p0.0159), 0.63 vs. 0.60 for diabetes (p0.0062), and 0.69
vs. 0.66 for chronic heart disease (p0.0441). However, persistence was not signif-
icantly different in either the overall cohort or the cohort stratified by comorbidity.
CONCLUSIONS: Our study suggests that use of SPC in hypertensive patients with
comorbidities may provide clinical benefits by improving better compliance com-
pared with patients taking FC.
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AWARENESS OF SERIOUS CONSEQUENCES OF NON-COMPLIANCE AND SELF-
REPORTED ADHERENCE TO ANTIPALTELET THERAPY AFTER PERCUTANEOUS
CORONARY INTERVENTION
Lee N1, Yu CM2, Lee VW2, Yan BP3
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OBJECTIVES: Premature discontinuation of antiplatelet therapy after percutane-
ous coronary intervention (PCI) is a main predictor of late stent thrombosis which
can lead to serious consequences such as death and acute myocardial infarction.
We aim to assess the impact of patients’ awareness of consequences of non-com-
pliance on self-reported adherence with antiplatelet therapy after PCI. METHODS:
We retrospectively analyzed 393 patients who underwent PCI with stent implan-
tation from the Care For Your Heart database in Hong Kong. Patients were asked
about their awareness of the risk of adverse cardiac events or death from non-
compliance with anti-platelet therapy after PCI. Patients who were non-compliant
(defined as self-reported missing more than 1 tablet per month) were compared to
those who were compliant. RESULTS: Of the 393 patients, 35.6% (n140) were
unaware that non-compliance with anti-platelet therapy was associated with any
risk, 50.9% (n235) was aware of risk of adverse cardiac events or death, and 5.9%
(n23) were considered non-compliant with prescribed antiplatelet therapy after
PCI. Non-compliant patients were predominantly male (91.3%) with an average age
of 67.00.9 years, of whom 43.5% were not aware that non-compliance was asso-
ciated with any risk compared to 35.9% (p0.03) of compliant patients. Patients
who were aware of the cardiac risks of non-compliance were more likely to adhere
to their anti-platelet regimen (48.2% vs. 28.1%; p0.03). More patients received their
information on cardiovascular health from health talks (60.3%) and printed media
(51.1%) than from their cardiologists (33.0%). CONCLUSIONS: Increased awareness
of the dire consequences of non-compliance with anti-platelet therapy is needed
among patients undergoing PCI. Health care providers are encouraged to better
educate patients to optimize adherence to medication.
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OBSERVATIONAL STUDY EVALUATING THE LEVEL OF COMPLIANCE WITH
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OBJECTIVES: To evaluate the level of compliance with antihypertensive medica-
tion among Greek hypertensive patients. Furthermore, to investigate the possible
association between non-compliance and patient profile as well as specific drug
categories. METHODS: A total of 2700 hypertensive patients participated and 2662
were analyzed in the study. The duration of the study was 9 months. Information
was collected on different antihypertensive drug categories along with epidemio-
logical data. Morisky scale was used in order to measure compliance. RESULTS: A
total of 57.5% of the responders were male (1530 patients) and 1130 were female.
Average age of responders was 63 years and average duration of hypertension was
8.6 years. 63.1% of the study population was found to be compliant with their
antihypertensive treatment (regardless of the type of antihypertensive treatment
the patient was receiving). From the Morisky scale, 36.2% of patients answered that
they sometimes forget to take their medication, 44.9% said that they were some-
times careless when it comes to taking their medicine, 26.9% that when they feel
better they forget to take their medicine and 18.4% of the study population an-
swered that when they feel worse, they relate this to their medication and discon-
tinue taking it. The factors found to influence compliance were the level of educa-
tion, the occupational status and the financial status of the patient as well as the
existence of conforming diseases such as duslipidemia and diabetes.
CONCLUSIONS: About four out of ten hypertensive patients fail to comply with
their prescribed treatment, increasing the possibility of poor control of their con-
dition. This may be an important obstacle in the assessment of the efficacy of any
pharmaceutical therapy and may influence the overall health levels of the patients,
since poorly controlled blood pressure may lead to the development of more seri-
ous conditions as Congestive Heart Failure and Coronary Heart Disease.
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ADHERENCE TO ANTIHYPERTENSIVE AGENTS AFTER A RECENT ISCHEMIC
STROKE AND RISK OF CARDIOVASCULAR OUTCOMES : A POPULATION BASED
STUDY
Perreault S1, Yu AYX2, Côté R2, Dragomir A3, White-guay B3, Dumas S3
1Université de Montréal, Montréal, QC, Canada, 2McGill University, Montreal, QC, Canada,
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OBJECTIVES:Antihypertensive agents have been shown to reduce the risk of major
cardiovascular events. However, there are no large effectiveness studies which
have assessed adherence to antihypertensive medications and major cardiovascu-
lar outcomes in high risk individuals who have recently suffered an ischemic
stroke. To evaluate the relationship between antihypertensive (AH) drug adher-
ence and cardiovascular (CV) outcomes among patients with a recent ischemic
stroke and to assess the validity of our approach. METHODS: A cohort of 14,227
patients with an ischemic stroke was assembled from individuals 65 years and
older who were treated with AH agents from 1999-2007 in the province of Quebec,
Canada. A nested case-control design was used to evaluate the occurrence of non-
fatal major CV outcomes, and mortality. Each case was matched to 15 controls by
age and cohort entry time. Medication possession ratio was used for AH agents
adherence level. Adjusted conditional logistic regression models were used to es-
timate the rate ratio of CV events. The validity of the approach was assessed by
evaluating the impact of adherence to CV protective and non-CV protective drugs.
RESULTS:Mean age was 75 years, 54% were male, 38% had coronary artery disease,
23% had diabetes, 47% dyslipidemia, and 14% atrial fibrillation or flutter. High
adherence to AH therapy decreased the risk of non-fatal vascular events compared
to lower level (Rate ratio: 0.77 (0.70-0.86). Male gender and CV disease were risk
factors for non-fatal vascular events. We observed a paradoxical relation between
adherence to several drugs and mortality risk. CONCLUSIONS: Adherence to AH
agents is associated with a risk reduction of non-fatal vascular events after a recent
ischemic stroke. Overestimation of an all-cause mortality reduction may be related
to frailty and comorbidity which may confound the apparent benefits of different
drugs.
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MISDIAGNOSIS AND MISTREATMENT OF ACE-INHIBITOR INDUCED COUGH
DECREASES THERAPY COMPLIANCE
Vegter S, de Boer P, van Dijk KW, Visser ST, de Jong-van den Berg LT
University of Groningen, Groningen, The Netherlands
OBJECTIVES: A common adverse effect of angiotensin-converting enzyme inhibi-
tors (ACEi) is a persistent dry cough. Physicians and pharmacists who fail to recog-
nise dry cough to be ACEi related may prescribe cough suppressants (antitussives),
instead of recommended ACEi substitution. The aim of this study was to determine
the amount of antitussive treatment of ACEi-induced cough and the influence of
this on therapy compliance. METHODS: Prescription data from community phar-
macies between 2000 and 2012 were retrieved from the IADB.nl database in The
Netherlands. A prescription sequence symmetry analysis was used to determine
whether antitussive agents were prescribed more often following ACEi initiation
than the other way around. Therapy compliance was assessed using the proportion
of days covered (PDC) method; patients with a PDC 80% were considered
compliant. RESULTS: A total of 1898 starters of ACEi and antitussives within a
half-year time span were included. A significant excess of patients received anti-
tussives after ACEi initiation (1,269 versus 629), yielding a sequence ratio of 2.0 (CI:
1.8–2.2). The estimated proportion of patients with ACEi induced cough receiving
antitussives decreased over time: from 20.4% in 2000-2004 to 8.0% in 2008-2012.
Therapy compliance in patients receiving antitussives due to ACEi initiation was
52.4%, significantly lower than compliance in control patients, which was 75.2%
(P0.001). CONCLUSIONS: Many patients receive cough suppressants after ACEi
initiation. This suggests that ACEi induced cough is often either not recognized as
being ACEi related or is symptomatically treated. Such prescription behaviour is
ineffective and potentially harmful; it also decreases therapy compliance with ACE
inhibitors. The correct identification and management of this adverse drug effect is
an important aspect of pharmaceutical care.
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PERSISTENCE OF PATIENTS TREATED HYPERTENSIVE MEDICATION IN PBM
WITH DIFFERENT PERCENTAGES OF FINANCIAL SUBSIDY
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OBJECTIVES: To evaluate medication persistence in patients hypertensive chronic
who have different percentages of financial subsidy in a Program Benefit Manage-
ment (PBM). METHODS: We identified patients from 3 health care providers with
different percentages of subsidy to buy a medication using the same service in PBM
the first provider subsidizes 100%, the second subsidizes 90% (generic) and 70%
(brand) and third subsidizes 40%. We selected patients with age  40 years male
and female. The persistence analysis was made in the 12 months that followed
from the first acquisition within the using method MPR (Medication Possession
Ratio).The drugs was Antagonist of Angiotensin II Receptor (Losartan),Beta-Blocker
(Atenolol), Calcium Channel Blocker (amlodipine) and an inhibitor of angiotensin
converting enzyme (Enalapril). RESULTS: The persistence obtained with first pro-
vider (subsidizes 100%) Amlodipine n1266 and a persistence of 77.25%, n1016
Atenolol and a persistence of 44.39%, n680 and Enalapril a persistence of 90.00%
and Losartan n1157 and a persistence of 81.16% as an overall average of persis-
tence between the four drugs was 73.20%, the second provider (subsidizes 90% for
generic drugs and 70% for brand) obtained - Amlodipine n1948 and a persistence
of 78.49%, n2061 Atenolol and a persistence of 32.07%, n1265 Enalapril and
persistence 84.19% of Losartan and n2.166 and a persistence of 73.36% as an
overall average of persistence between four drugs 67.03% and the third provider
(subsidizes 40%), Amlodipine n1264 and a persistence of 9.34%, n1471 Atenolol
and a persistence of 9.11%, n941 Enalapril and a persistence of 36.88% and Losar-
tan n1917 and a persistence of 29.47% as a general average of persistence of the
four 21.20% drugs. CONCLUSIONS: The average persistence varies statistically sig-
nificantly with the percentage of subsidy the benefit influencing directly the per-
sistence of these populations, the greater the allowance / benefit was greater at the
rate of persistence between them.
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THE BURDEN OF NON-ADHERENT PRESCRIPTION COST CUTTING AMONG
DIAGNOSED HYPERTENSION PATIENTS IN RUSSIA
Gupta S1, Vietri J1, DiBonaventura MD2
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OBJECTIVES: To determine loss of health status, work productivity impairment,
and activity impairment associated with non-adherent cost-cutting in Russian hy-
pertension patients. METHODS: The study employed data from the 2011 Russia
National Health and Wellness Survey (NHWS; n10,039), a survey of demograph-
ics, health-related attitudes and behaviors, and health outcomes. Non-adherent
cost-cutting behaviors included taking less medication than prescribed, cutting
tablets in half, buying fewer tablets, not buying prescriptions recommended by the
physician, buying a less expensive alternative instead, or buying prescriptions less
often. Adherent behaviors included asking physician/ pharmacist for cheaper al-
ternatives, or using a discount card. Health status was assessed using the SF-12v2,
and work and activity impairment using the Work and Activity Impairment ques-
tionnaire (WPAI). Regression models quantified the burden associated with non-
adherent cost-cutting on health status and WPAI metrics, controlling for demo-
graphics, health history, insurance status, and comorbidities. RESULTS: Out of
1,712 diagnosed hypertension patients taking prescription medication for hyper-
tension, 37.5% reported using non-adherent cost-cutting behaviors, 28.2% reported
using adherent cost-cutting behaviors only, and 34.3% reported no cost-cutting
behaviors. After controlling for covariates, employed patients using non-adherent
strategies reported greater absenteeism (9.3% vs. 3.7%, p0.002), presenteeism
(29.2% vs. 21.8%, p0.001) and overall work productivity loss (33.8% vs. 24.3%,
p0.001) compared with employed patients who do not use those strategies.
Among all respondents, non-adherent cost-cutting was associated with lower ad-
justed health status (MCS: 42.0 vs. 44.4, p0.001, PCS: 40.3 vs. 41.3, p0.014) and
greater adjusted activity impairment (38.5% vs. 31.2%, p0.001). CONCLUSIONS:
Over a third of hypertension patients cut costs using strategies that interfere with
medication adherence. These patients suffer greater health-related impairments
in work and non-work activities and have lower health status. These patients
should be identified and guided to improve adherence to their prescription medi-
cations to facilitate better health outcomes.
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FACTORS RELATED TO NON-ADHERENCE AND SATISFACTION FOR
HYPERTENSION MEDICATIONS: RESULTS FROM A NOVEL PATIENT REGISTRY
Kamble S1, Cascade E2, Gemmen E1
1Quintiles Outcome, Rockville, MD, USA, 2Quintiles, Inc., Rockville, MD, USA
OBJECTIVES:Medication non-adherence and treatment satisfaction are significant
barriers to achieving treatment outcomes and associated with increased health
care costs among patients with hypertension. Using a novel patient registry, we
assessed factors associated with satisfaction and non-adherence to hypertension
medications.METHODS:We analyzed data from MediGuard.org, a free medication
monitoring service covering over 2.6 million members in the US, UK, France, Ger-
many, Spain, and Australia. As part of site operations, the service sends a quarterly
member survey to solicit feedback on their medications using the Treatment Sat-
isfaction Questionnaire for Medication (TSQM) and Medication Adherence Report
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